



This report is prepared for the Warsaw Stock Exchange SA within the framework of the Analytical Coverage Support Program 3.0.

Daily 26.IX.2022

| Company | LT fundamental recommendation | 12M EFV (PLN) | ST market-relative bias | Analyst |
|------------------|-------------------------------|---------------|-------------------------|---|
| BioMaxima | Not rated | 37.1 | Not rated | Sylvia Jaśkiewicz, CFA Mikołaj Stępień |

Event: Buyback update

The Company informed that a number of own shares purchased in the pending buyback reached 177 300 shares (4.1% of the share capital), which implies PLN c. 27.75 per share. BioMaxima has already used 98% of the funds earmarked for the buyback (PLN 5 million).

Expected impact: *Neutral.*

The report is not a recommendation within the meaning of Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest.